We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Computer Algorithms Automatically Detect Malaria in Stained Blood Smears

By LabMedica International staff writers
Posted on 10 Aug 2015
An Israeli startup company has developed a computerized platform that detects anomalies in stained blood cell samples—such as those infected by the malaria parasite—faster and more accurately than the human eye.

Sight Diagnostics or SightDx (Jerusalem, Israel) was initiated in 2011 with six million USD obtained from crowd funding and several innovation investors. More...
This funding was used by a team comprising biologists, software experts, and engineers to develop vision-based algorithms to scan and analyze blood. Analysis was based on visible characteristics such as size, shape, fluorescence intensity, and morphology.

The algorithms were set to function within SightDx's Parasight platform, a high throughput instrument suitable for batch (up to 30 samples) and asynchronous loading. It was designed to be fully automated, simple to operate, and optimized for rapid testing and analysis.

The Parasight platform consists of a scanning and analyzing device as well as a sample preparation kit containing custom-built disposable plastic cartridges to create an efficient, standardized, and uniform version of the “thin blood smear”, that is easy to prepare within 15 seconds. These cartridges require only a small drop of blood that can be obtained with a finger-stick or from a tube. Parasight reports, in under three minutes, the diagnosis (Positive/Negative), parasitemia count (number of parasites per microliter), and speciation (determination of the specific species of malaria). Results are automatically transferred to the laboratory information system.

Trials using Parasight were conducted in several hospitals in India, South Africa, and France. Results showed that it was 99% accurate in sensitivity and 98% in specificity as compared to results of about 95% for human microscopists.

“Essentially, you try to do what the human eye does,” said Joseph Joel Pollak, CEO of Sight Diagnostics. “Computer vision-based devices have a camera, and the camera takes pictures of the blood. Then, algorithms analyze the scene.”

Related Links:

Sight Diagnostics



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.